Rigel to Present at the Jefferies Global Healthcare Conference

Rhea-AI Summary

Rigel (Nasdaq:RIGL) announced that president and CEO Raul Rodriguez will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 8:45 a.m. ET in New York.

Investors can access a live webcast and archived replay via Rigel's investor relations website.

News Market Reaction – RIGL

+1.06%

+1.06% Session close to close

In the May 27 session, RIGL gained 1.06%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Rigel’s upcoming presentation at a major healthcare investor conference...

Analysis

This announcement highlights Rigel’s upcoming presentation at a major healthcare investor conference, which primarily serves as a visibility and relationship-building event rather than a defined value inflection. Recent history shows more meaningful stock reactions around licensing deals and quarterly results, such as the VEPPANU™ agreement and Q1 revenue of $58.8M. Investors may watch for any new strategic disclosures around the broader hematology-oncology franchise and how they complement existing commercial assets.

Key Figures

Conference date: June 3, 2026 Presentation time: 8:45 a.m. ET Founding year: 1996

3 metrics

Conference date June 3, 2026 Jefferies Global Healthcare Conference presentation time

Presentation time 8:45 a.m. ET Jefferies conference company overview slot

Founding year 1996 Year Rigel Pharmaceuticals was founded

Historical Context

5 past events · Latest: May 21 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 21	Oncology data presentations	Positive	-0.6%	New data on GAVRETO, REZLIDHIA, and TAVALISSE at ASCO and EHA.
May 14	Investor conference appearance	Neutral	-0.7%	CFO company overview at RBC Global Healthcare Conference.
May 12	Licensing deal announcement	Positive	+12.1%	Exclusive global license for VEPPANU for advanced breast cancer.
May 05	Quarterly earnings results	Positive	-5.1%	Q1 2026 revenue, net income and reaffirmed full-year guidance.
Apr 28	Earnings call scheduling	Neutral	+0.2%	Announcement of Q1 2026 earnings release and conference call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news shows 3 aligned and 2 divergent price reactions, with positive fundamental or deal news sometimes followed by short-term pullbacks.

Recent Company History

Over the last months, Rigel reported Q1 2026 revenue of $58.8M with net income of $8.7M and reaffirmed $275–$290M 2026 revenue guidance, yet shares fell 5.06% the next day. An exclusive global license for VEPPANU™ with up to $70M upfront and other payments saw a 12.1% gain. Multiple conference-related announcements (ASCO/EHA data, RBC conference) had small, mixed reactions, suggesting non-fundamental events often move the stock modestly.

Key Terms

hematologic disorders, investor relations

2 terms

hematologic disorders medical

"novel therapies that significantly improve the lives of patients with hematologic disorders and cancer."

Hematologic disorders are diseases that affect the blood and the organs that make blood, such as conditions causing low blood counts, abnormal clotting, or cancers of blood-forming cells. For investors, these disorders matter because they define markets for diagnostics, treatments and long-term care—think of them as problems in a city’s delivery and maintenance system: fixing them can create commercial opportunities, while persistent unmet needs can drive regulatory attention and spending.

investor relations financial

"visit the Investor Relations section of the company's website at www.rigel.com."

Investor relations is the communication process between a company and its current or potential investors. It involves sharing information about the company's performance, strategies, and outlook to help investors make informed decisions. Effective investor relations build trust and transparency, similar to a clear conversation between a business and someone considering investing, ensuring both parties understand each other's interests and expectations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., May 27, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 8:45 a.m. ET in New York, NY.

To access the live webcast or archived recording, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads.

About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com.

Contact for Investors & Media:
Investors: 
Rigel Pharmaceuticals, Inc. 
650.624.1232 
ir@rigel.com

Media:
David Rosen 
Argot Partners 
646.461.6387
david.rosen@argotpartners.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-to-present-at-the-jefferies-global-healthcare-conference-302782544.html

SOURCE Rigel Pharmaceuticals, Inc.

FAQ

When will Rigel (RIGL) present at the Jefferies Global Healthcare Conference in 2026?

Rigel will present on Wednesday, June 3, 2026, at 8:45 a.m. ET. According to Rigel, president and CEO Raul Rodriguez will deliver a company overview during the Jefferies Global Healthcare Conference in New York.

Who is presenting for Rigel (RIGL) at the Jefferies Global Healthcare Conference 2026?

Rigel’s president and CEO Raul Rodriguez will present at the conference. According to Rigel, he will provide a company overview to investors and analysts at the Jefferies Global Healthcare Conference in New York.

How can investors access the Rigel (RIGL) webcast from the Jefferies Global Healthcare Conference?

Investors can access a live webcast and archived recording via Rigel’s investor relations website. According to Rigel, visitors should connect to the site before the start to complete any required software downloads.

What will Rigel (RIGL) present at the Jefferies Global Healthcare Conference 2026?

Rigel will present a company overview at the Jefferies Global Healthcare Conference. According to Rigel, the presentation will focus on its biotechnology business in hematologic disorders and cancer and can be followed via webcast.

Where is the 2026 Rigel (RIGL) Jefferies Global Healthcare Conference presentation taking place?

The Rigel presentation will take place in New York, NY. According to Rigel, the Jefferies Global Healthcare Conference session featuring CEO Raul Rodriguez is scheduled for June 3, 2026, at 8:45 a.m. ET.